The European Union has some 20 "biosimilar" generics on the market; the US has one.

Drug makers are raising concerns Brexit could delay regulatory approval, slow down funding for basic research

Big drug companies today have remade their business models.

It's the seventh such deal for the insurance giant, which is putting pressure on drug makers in an effort to keep costs down.

Hedge funds are joining groups who want to lower prescription prices for consumers.

A new proposal to cut Medicare drug spending costs has left doctors fuming.

The industry worries it's a step toward price controls.

It's not just a few bad players, as Congressional hearing puts drug costs in focus.